If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Seeded second at the Italian Open, he reached the semifinals defeating Cristian Garín in the quarterfinals. In the semifinals, he faced fourth seed, Stefanos Tsitsipas, again for the third consecutive time at this Masters level in the clay court season. He lost his semifinal match to Tsitsipas in three sets. Seeded third at the French Open, Zverev matched his semifinal result from the previous year, defeating sixth seed, Carlos Alcaraz, in the quarterfinals in what was his first top-10 victory at a major after 12 attempts. In his semifinal match against fifth seed, former world No. 1, and 13 time Roland Garros champion, Rafael Nadal, he retired 3 hours and 13 minutes into the match after rolling his right ankle and tearing all three lateral ligaments. He was rolled off the court in a wheelchair. Zverev informed that the injury would cause him to miss the 2022 Wimbledon Championships and on 8 June 2022 underwent surgery to repair the torn ligaments in his ankle. Despite his exit at Roland Garros, he reached a career-high ranking of world No. 2 on 13 June 2022. In September, he was due to return for the Davis Cup play but suffered a new injury, a bone edema, and withdrew from competition for the rest of the season. Zverev ended the year ranked 12, his lowest in five years, when he debuted in the top 10 and remained a fixture there.
With the destruction of the Zaporizhian Sich, a number of Ukrainian-speaking Eastern Orthodox Zaporozhian Cossacks fled to the territory under the control of the Ottoman Empire. Together with Cossacks of Greater Russian origin, as well as the vast majority of Old Believers and other people from "Greater Russia" (Muscovy), they settled in the area of the Danube river, and founded a new Sich. Many Ukrainian peasants and adventurers later joined the Danubian Sich. While Ukrainian folklore remembers the Danubian Sich, other new siches of Loyal Zaporozhians on the Bug and Dniester rivers did not achieve such fame. Other Cossacks settled on the Tisa river in the Austrian Empire, also forming a new Sich. During the Cossack sojourn under Turkish rule, a new host was founded that numbered around 12,000 people by the end of 1778. Cossack settlement on the Russian border was approved by the Ottoman Empire after the Cossacks officially vowed to serve the sultan. Yet internal conflict, and the political maneuvering of the Russian Empire led to splits among the Cossacks. Some of the runaway Cossacks returned to Russia, where the Russian army used them to form new military bodies that also incorporated Greeks, Albanians and Crimean Tatars. After the Russo-Turkish war of 1787–1792, most of these Cossacks were absorbed into the Black Sea Cossack Host together with Loyal Zaporozhians. Most of the remaining Cossacks who had stayed in the Danube Delta returned to Russia in 1828. They settled in the area north of the Azov Sea, becoming known as the Azov Cossacks.
== Function == The α-macroglobulin (αM) family of proteins includes protease inhibitors, typified by the human tetrameric α2-macroglobulin (α2M); they belong to the MEROPS proteinase inhibitor family I39, clan IL. These protease inhibitors share several defining properties, which include (1) the ability to inhibit proteases from all catalytic classes, (2) the presence of a 'bait region' (also known as a sequence of amino acids in an α2-macroglobulin molecule, or a homologous protein, that contains scissile peptide bonds for those proteinases that it inhibits) and a thiol ester, (3) a similar protease inhibitory mechanism and (4) the inactivation of the inhibitory capacity by reaction of the thiol ester with small primary amines. αM protease inhibitors inhibit by steric hindrance. The mechanism involves protease cleavage of the bait region, a segment of the αM that is particularly susceptible to proteolytic cleavage, which initiates a conformational change such that the αM collapses about the protease. In the resulting αM-protease complex, the active site of the protease is sterically shielded, thus substantially decreasing access to protein substrates. Two additional events occur as a consequence of bait region cleavage, namely (1) the h-cysteinyl-g-glutamyl thiol ester becomes highly reactive and (2) a major conformational change exposes a conserved COOH-terminal receptor binding domain (RBD). RBD exposure allows the αM protease complex to bind to clearance receptors and be removed from circulation.
Sources: en.wikipedia.org
=== Pancreatic === Although most of the glucokinase in the body is in the liver, smaller amounts in the beta and alpha cells of the pancreas, certain hypothalamic neurons, and specific cells (enterocytes) of the gut play an increasingly appreciated role in regulation of carbohydrate metabolism. In the context of glucokinase function, these cell types are collectively referred to as neuroendocrine tissues, and they share some aspects of glucokinase regulation and function, especially the common neuroendocrine promoter. Of the neuroendocrine cells, the beta cells of the pancreatic islets are the most-studied and best-understood. It is likely that many of the regulatory relationships discovered in the beta cells will also exist in the other neuroendocrine tissues with glucokinase.
In December 2013, NSF launched a lawsuit against MusclePharm and declared that MusclePharm is not authorized to use any NSF certification marks, to claim that any of its products are certified by NSF, or to claim that they have been manufactured in an NSF GMP certified or registered facility. The Tawnsaura Group sued MusclePharm for patent infringement. 2011 Environmental Research Center (ERC) filed a notice of intent to start litigation against over 200 nutrition and supplement companies, including MusclePharm, alleging violations of California Proposition 65. I'm a lawsuit, ThermoLife claimed that MusclePharm infringed ThermoLife's patent on amino acid compounds including creatine nitrate. 2006 MusclePharm was first incorporated.
In regions such as the gingiva and parts of the hard palate, oral mucosa is attached directly to the periosteum of underlying bone, with no intervening submucosa. This arrangement is called a mucoperiosteum and provides a firm, inelastic attachment. A variable number of Fordyce spots or granules are scattered throughout the nonkeratinized tissue. These are a normal variant, visible as small, yellowish bumps on the surface of the mucosa. They correspond to deposits of sebum from misplaced sebaceous glands in the submucosa that are usually associated with hair follicles. A basal lamina (basement membrane without aid of the microscope) is at the interface between the oral epithelium and lamina propria similar to the epidermis and dermis.
Sources: en.wikipedia.org
On 22 September 2014, VESA published the DisplayPort Alternate Mode on USB Type-C Connector Standard, a specification on how to send DisplayPort signals over the newly released USB-C connector. One, two or all four of the differential pairs that USB uses for the SuperSpeed bus can be configured dynamically to be used for DisplayPort lanes. In the first two cases, the connector still can carry a full SuperSpeed signal; in the latter case, at least a non-SuperSpeed signal is available. The DisplayPort AUX channel is also supported over the two sideband signals over the same connection; furthermore, USB Power Delivery according to the newly expanded USB-PD 2.0 specification is possible at the same time. This makes the Type-C connector a strict superset of the use cases envisioned for DockPort, SlimPort, and Mini and Micro DisplayPort. However, DisplayPort Dual-Mode (DP++) is not supported under USB-C alternate mode.
== Fragments == Big dynorphin1-32 is the primary endogenously documented big dynorphin form, but various shorter big dynorphin fragments have been synthesized for research purposes. These include (2-32), (2-26), (9-19) forms.
The cap is 1.6–8 cm (3⁄4–3+1⁄4 in), conic to convex with a central papilla when young, becoming broadly convex to plane with age, retaining a slight umbo sometimes surrounded by a ring-shaped depression. The cap surface is smooth and sticky, sometimes with white universal veil remnants attached. The cap is brown becoming paler to almost white at the margin and fades to more golden-brown or yellowish with age. When bruised, all parts of the mushroom stain blue. The narrow grey gills are adnate to adnexed, sometimes seceding attachment, and darken to purplish-black and somewhat mottled with age. The gill edges remain whitish. The hollow white stipe is 4–15 cm (2–6 in) high by 0.4–1.4 cm (1⁄4–1⁄2 in) thick, becoming yellowish in age. The well-developed veil leaves a persistent white membranous ring whose surface usually becomes the same color as the gills because of falling spores. The fruiting bodies are 90% water. The mushroom has no odor and has been described as tasting farinaceous, with an alkaline or metallic aftertaste. The spores are 11.5–17.3 x 8–11.5 μm, sub-ellipsoid, basidia 4-spored but sometimes 2- or 3-, pleurocystidia and cheilocystidia present.
For an odd-numbered saturated fat (Cn), 0.5 * n - 1.5 oxidations are necessary, and the final process yields 8 acetyl CoA and 1 propionyl CoA. It is then converted to a succinyl CoA by a carboxylation reaction and generates additional 5 ATP (1 ATP is consumed in carboxylation process generating a net of 4 ATP). In addition, two equivalents of ATP are lost during the activation of the fatty acid. Therefore, the total ATP yield can be stated as:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.